Stamford, Conn.-based hedge fund advisory firm CR Intrinsic Investors, an affiliate of S.A.C. Capital, agreed to pay more than 600 million to settle SEC charges that it participated in an insider trading scheme involving a clinical trial for an Alzheimer's drug being jointly developed by two pharmaceutical companies.